Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Omada Health shares climbed after the company made its debut on Nasdaq. The virtual healthcare company started trading shares at $19 on Friday morning, and they jumped 35% to $25.58 by midday. It ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

Novo Nordisk's flagship diabetes and weight-loss drugs, Ozempic and Wegovy, have come under heightened scrutiny after the ...

Patients who use GLP1 drugs to help control their type 2 diabetes are at an upward risk of developing age-related macular ...

These five Dow Jones industrial companies have paid dividends to shareholders for at least 100 years, perfect ideas for ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...